Published online Apr 26, 2024.
https://doi.org/10.4070/kcj.2023.0241
Cardiovascular Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Updated Meta-Analysis
,1
Mateus M. Gauza, MD,2
Larissa Teixeira, MD,1
Maria Eduarda S. Guisso, MD,2
Alleh Nogueira,3
Caroline S. Dagostin, MD, MSc,4
Amanda Godoi, BSc,
Sandro A. G. Ribeiro, MD,6
Juan C. Duque, MD,7
José A. Moura-Neto, MD, FASN, FRCP,3
and Rhanderson Cardoso, MD, MHS, FACC8
Author's summary
This meta-analysis of randomized trials comprised 29,146 patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) and investigated the efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) compared with placebo. SGLT2i therapy significantly reduced all-cause mortality, composite of cardiovascular mortality or hospitalizations for heart failure (HHF), cardiovascular mortality, HHF, major adverse cardiovascular events, stroke, myocardial infarction, and CKD progression. Results were consistent across different levels of kidney function, albeit with a benefit in stroke for patients with lower residual renal function. In conclusion, SGLT2i in patients with T2DM and CKD reduced cardiovascular and renal complications compared with placebo.
Graphical Abstract
Abstract
Background and Objectives
The efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) may depend on renal function, and this raises theoretical concern over its effects on cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD).
Methods
This systematic review and updated meta-analysis of randomized controlled trials (RCTs) compared cardiovascular outcomes of patients with T2DM and CKD treated with SGLT2i to placebo. PubMed, Embase, and Cochrane were systematically searched. Prespecified subgroup analyses were performed in strata of estimated glomerular filtration rate (eGFR) of <45 mL/min/1.73 m2 and 45 to 59 mL/min/1.73 m2.
Results
Nine RCTs comprising 29,146 patients were selected. Average follow-up ranged from 0.75 to 4.2 years. SGLT2i were shown to reduce the risk of all-cause mortality (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.79–0.97; p=0.01), the composite of cardiovascular mortality or hospitalizations for heart failure (HHF: HR, 0.71; 95% CI, 0.65–0.78; p<0.001), cardiovascular mortality (HR, 0.86; 95% CI, 0.76–0.98; p=0.02), HHF (HR, 0.62; 95% CI, 0.55–0.71; p<0.001), major adverse cardiovascular events (HR, 0.85; 95% CI, 0.77–0.94; p=0.002), stroke (HR, 0.76; 95% CI, 0.59–0.97; p=0.03), and myocardial infarction (HR, 0.78; 95% CI, 0.67–0.91; p=0.001). These findings were consistent over strata of eGFR, albeit with a lower incidence of stroke in patients treated with SGLT2i with eGFR <45 mL/min/1.73 m2 (p-value for interaction=0.04).
Conclusions
Compared with a placebo, patients with T2DM and CKD treated with SGLT2i experience a reduction in all-cause mortality, cardiovascular mortality, and HHF.
Trial Registration
PROSPERO Identifier: CRD42023401081
INTRODUCTION
Type 2 diabetes mellitus (T2DM) places a high economic burden on healthcare systems due to diabetes-related, cardiovascular, and metabolic complications.1) In 2017, approximately 462 million people worldwide were diagnosed with diabetes mellitus, corresponding to 6.28% of the overall population.2) Diabetes is the leading cause of end-stage kidney disease and renal replacement therapy worldwide.3) Chronic kidney disease (CKD) is also an important risk factor for cardiovascular disease, and individuals with both CKD and T2DM are at greater cardiovascular risk compared with T2DM alone.4)
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular mortality, major cardiovascular events (MACE), nonfatal myocardial infarction (MI), and nonfatal stroke in patients with T2DM.5), 6), 7), 8), 9), 10) In addition, some have shown favorable results of SGLT2i in patients with T2DM and CKD, with a reduction in the composite of cardiovascular mortality or hospitalizations for heart failure (HHF), MI, and stroke.5), 6), 7), 9)
However, the efficacy of SGLT2i in reducing other cardiovascular endpoints in this population is unclear. In the CREDENCE trial, for example, there was no significant difference in cardiovascular or all-cause mortality between patients with CKD and T2DM treated with SGLT2i vs. placebo.5) Yet, such trials have studied patients with different cardiometabolic and renal function profiles. Given that the therapeutic effects of SGLT2i are influenced by glomerular filtration rate, there is still uncertainty regarding its actual impact in this population.11)
Previous meta-analyses on the cardiovascular effects of SGLT2i in patients with T2DM and CKD have also shown conflicting results.12), 13) Those studies, however, were published before large prospective multicenter trials in this patient population, such as EMPA-KIDNEY, SCORED, and VERTIS CV.7), 9), 10)
Therefore, we aimed to undertake a systematic review and updated meta-analysis assessing the clinical cardiovascular outcomes of SGLT2i compared with placebo in a population with T2DM and concomitant CKD.
METHODS
The prospective meta-analysis protocol has been uploaded to the International Prospective Register of Systematic Reviews (PROSPERO; CRD42023401081).
Eligibility criteria
Inclusion in this systematic review and meta-analysis was restricted to studies that met all the following eligibility criteria: 1) randomized controlled trials (RCTs); 2) comparing SGLT2i with placebo; and 3) enrolling patients who had both CKD and T2DM. Definitions of CKD varied slightly among included studies, as outlined in Table 1. Studies focused on a population of patients with CKD or T2DM were included only if outcomes were reported on a subgroup of patients with both CKD and T2DM. We excluded studies without outcomes of interest in this specific patient population.
Table 1
Individual study characteristics
Endpoints and subanalyses
The efficacy outcomes were all-cause mortality, cardiovascular mortality, stroke, MI, major adverse cardiovascular events (MACE), HHF, and a composite of cardiovascular mortality or HHF or urgent visits for heart failure. MACE was defined as the 3-point composite of cardiovascular mortality, MI, or stroke. We performed subgroup analyses of the outcomes of interest according to estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 and 45 to 59 mL/min/1.73 m2.
To secondarily explore the renal effects of SGLT2i in these patients, we analyzed the composite of CKD progression. The definitions for MACE and CKD progression are displayed in Supplementary Table 1.
Search strategy and data extraction
We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception to February 2023 with the following search terms: 'RCT', ‘randomized’, ‘random’, ‘randomly’, ‘SGLT2 inhibitors’, ‘sodium-glucose cotransporter-2’, ‘SGLT2i’, ‘canagliflozin’, ‘dapagliflozin’, ‘empagliflozin’, ‘sotagliflozin’, ‘ertugliflozin’, ‘diabetes’, ‘type 2 diabetes’, ‘chronic kidney disease’, ‘CKD’, ‘nephropathy’, ‘cardiovascular’, ‘cardiac’, and ‘heart’. No filters or language limitations were applied in our search.
We also performed a technique of backward snowballing, searching for additional eligible studies through a review of the references from prior publications, including meta-analyses and included studies. Two authors (N.F. and M.M.G.) performed the literature search independently. Three authors (L.T., M.M.G., and N.F.) conducted the data extraction from included studies following predefined criteria and quality assessment. Eventual conflicts were resolved through consensus among the authors.
Risk of bias and sensitivity analyses
Quality assessment of RCTs was performed using the Cochrane Collaboration’s tool for assessing risk of bias in randomized trials (RoB-2), in which studies are scored as high, low, or unclear risk of bias in 5 domains: selection, performance, detection, attrition, and reporting biases. We also performed funnel plot analysis to appraise potential small study effects (publication bias) and sensitivity analyses using the leave-one-out strategy.
Statistical analysis
The systematic review and meta-analysis were performed in accordance with the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines.14) Endpoints were primarily analyzed with a hazard ratio (HR) with 95% confidence intervals (CIs) to compare treatment effects preserving time-to-event data. To include trials that did not report time-to-event analyses, we also computed the odds ratio (OR) for the outcomes reported in such trials. Cochran Q test and I2 statistics were used to assess heterogeneity; p-values inferior to 0.10 and I2≥25% were considered significant. We used a fixed-effect model for outcomes with low heterogeneity (I2<25%). Otherwise, we chose the DerSimonian and Laird random-effect model. Review Manager 5.4 (Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and R (R Foundation for Statistical Computing, Vienna, Austria) version 4.1.2 were used for statistical analyses. Furthermore, we performed a weighted random-effects meta-regression to examine sources of heterogeneity and interactions in treatment effects for the outcome of MACE.
RESULTS
Study selection and characteristics
Our initial search yielded 1,722 results. After removing duplicate records and ineligible studies, 52 remained for full-text revision based on our previously detailed inclusion criteria (Figure 1). Of these, nine RCTs were included, with a total of 29,146 patients. Study characteristics are reported in Table 1.
Figure 1
PRISMA flow diagram of study screening and selection.
CKD = chronic kidney disease; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis; SGLT2i = sodium-glucose cotransporter-2 inhibitors; T2DM = type 2 diabetes mellitus.
Pooled analysis of all studies
Patients randomized to SGLT2i had lower all-cause mortality when compared with those taking placebo (HR, 0.88; 95% CI, 0.79–0.97; p=0.01; I2=0%; Figure 2A). Similarly, cardiovascular mortality (HR, 0.86; 95% CI, 0.76–0.98; p=0.02; I2=0%; Figure 2B) and the composite of cardiovascular mortality or HHF (HR, 0.71; 95% CI, 0.65–0.78; p<0.001; I2=0%; Figure 2C) were also reduced in the SGLT2i group.
Figure 2
(A) All-cause mortality; (B) cardiovascular mortality; and (C) the composite of cardiovascular mortality or hospitalizations for heart failure were significantly lower in the SGLT2 inhibitor group, with low heterogeneity among studies (I2=0%).
CI = confidence interval; df = degrees of freedom; IV = inverse variance; SE = standard error; SGLT2i = sodium-glucose cotransporter-2 inhibitors.
As event rates, results from the subpopulation of patients with both T2DM and CKD in the EMPA-KIDNEY trial were obtained directly from the authors.7) Therefore, we also performed statistical analyses using OR, such that the results from the EMPA-KIDNEY trial could also be included. In these analyses, cardiovascular mortality (OR, 0.82; 95% CI, 0.72–0.94; p=0.005; I2=0%; Figure 3A) and the composite of cardiovascular mortality or HHF (OR, 0.74; 95% CI, 0.67–0.81; p<0.001; I2=0%; Figure 3B) remained significantly reduced with SGLT2i relative to placebo.
Figure 3
In the analysis including the EMPA-KIDNEY trial, with OR, (A) cardiovascular mortality and (B) the composite of cardiovascular mortality or hospitalizations for heart failure were significantly reduced with SGLT2i therapy, with low heterogeneity among studies (I2=0%).
CI = confidence interval; df = degrees of freedom; M-H = Mantel Haenszel test; OR = odds ratio; SGLT2i = sodium-glucose cotransporter-2 inhibitors.
Patients in the SGLT2i group had a significantly lower risk of HHF than the placebo group (HR, 0.62; 95% CI, 0.55–0.71; p<0.001; I2=0%; Figure 4). We also found the SGLT2i group to be at substantially lower risk than the placebo group with regards to MACE (HR, 0.85; 95% CI, 0.77–0.94; p=0.002; I2=30%; Figure 5A); MI (HR, 0.78; 95% CI, 0.67–0.91; p=0.001; I2=10%; Figure 5B); and stroke (HR, 0.76; 95% CI, 0.59–0.97; p=0.03; I2=41%; Figure 5C).
Figure 4
Patients on SGLT2i were at a substantially lower risk for HHF than those on placebo.
CI = confidence interval; df = degrees of freedom; HHF = hospitalizations for heart failure; IV = inverse variance; SE = standard error; SGLT2i = sodium-glucose cotransporter-2 inhibitors.
Figure 5
(A) MACE; (B) MI; and (C) Stroke were significantly less frequent in the SGLT2i group, with some heterogeneity among studies (I2=30%; I2=10%; I2=41%).
CI = confidence interval; df = degrees of freedom; IV = inverse variance; MACE = major cardiovascular events; MI = myocardial infarction; SE = standard error; SGLT2i = sodium-glucose cotransporter-2 inhibitors.
Compared with placebo, SGLT2i therapy significantly reduced CKD progression (HR, 0.64; 95% CI, 0.57–0.71; p<0.001; I2=0%; Figure 6).
Figure 6
SGLT2i significantly reduced CKD progression (p<0.001).
CI = confidence interval; CKD = chronic kidney disease; df = degrees of freedom; IV = inverse variance; SE = standard error; SGLT2i = sodium-glucose cotransporter-2 inhibitors.
Subgroup analyses
We performed subgroup analyses stratified by categories of eGFR: 1) <45 mL/min/1.73 m2 and 2) 45–59 mL/min/1.73 m2. Cardiovascular mortality was significantly lower in the SGLT2i group than placebo, without statistically significant interaction between strata of eGFR (Supplementary Figure 1). Similarly, HHF (Supplementary Figure 2) and MACE (Supplementary Figure 3) were significantly reduced by SGLT2i compared with placebo in the subgroup of patients with eGFR <45 and 45–59 mL/min/1.73 m2.
The incidence of stroke was significantly reduced in the group of patients with eGFR <45 mL/min/1.73m2 who were treated with SGLT2 inhibitors (HR, 0.50; 95% CI, 0.31–0.79; p=0.003; Supplementary Figure 4). In those with eGFR 45–59 mL/min/1.73 m2, there was no significant difference between treatment groups (HR, 0.92; 95% CI, 0.66–1.28; p=0.61; Supplementary Figure 4). There was a statistically significant interaction (p=0.04) for eGFR subgroup differences in the treatment effect of SGLT2 inhibitor versus placebo for the outcome of stroke.
The rate of MI was not significantly different between SGLT2i and placebo in subgroups of patients with CKD stratified by eGFR (Supplementary Figure 5). There was no evidence of interaction between eGFR and the treatment effect in terms of MI (p=0.64).
Quality assessment
The Cochrane Collaboration’s tool for assessing RoB-2 was used for quality assessment. All RCTs were labeled as having a low risk of bias, as described in Supplementary Figure 6. Funnel plot analysis for publication bias was limited by the low number of studies within one outcome (seven studies for the outcome of MACE). However, there was no significant asymmetry in the distribution of treatment effects of studies with similar weights, which suggests no evidence of publication bias (Supplementary Figure 7).
Meta-regression
We performed meta-regression analyses to evaluate for sources of heterogeneity and potential treatment interactions (Supplementary Figure 8). Across studies, treatment effects for MACE did not differ significantly according to the prevalence of female gender (p=0.12), patients with heart failure (p=0.76), patients with cerebrovascular disease (p=0.79), and follow-up time (p=0.39) among studies.
DISCUSSION
In this meta-analysis of nine RCTs, we compared SGLT2i with placebo in 29,146 patients with T2DM and concomitant CKD. The main findings were as follows: 1) SGLT2i were associated with a 12% relative reduction in all-cause mortality and 14% reduction in cardiovascular mortality; 2) HHF were also significantly reduced by SGLT2i, with a relative risk reduction of 38%; 3) SGLT2i were also associated with a significant reduction in MACE, stroke, and MI in this patient population; and 4) findings were generally consistent across subgroups of eGFR (<45 and 45–59 mL/min/1.73 m2). However, there was a significant interaction between strata in the outcome of stroke, with a benefit of SGLT2i in patients with lower eGFR (<45 mL/min/1.73 m2).
SGLT2i are widely used in the treatment of T2DM. They block glucose and sodium reuptake in the proximal renal tubule, thus promoting glycosuria.15) A key factor for cardiovascular protection with SGLT2i use is the reduction of plasma volume due to its natriuretic and osmotic effects. This leads to a reduction in preload and afterload, which may be especially beneficial for decreasing the risk of HHF.15) Other proposed mechanisms for its cardiovascular benefits include reduction of oxidative stress, renin-angiotensin-aldosterone system blockade, and attenuation of myocardial remodeling.16)
As for renal protective pathways, SGLT2i improves renal oxygenation and reduces glomerular hypertension and hyperfiltration by tubuloglomerular feedback reduction and improvement in the albuminuria, which are essential mechanisms of diabetic nephropathy pathogenesis and cardiovascular risk predictors in nondiabetic and diabetic patients.17), 18), 19) Even beyond the scope of diabetes, this class of medications has been vastly studied in the past years, and several large-scale clinical trials have also shown cardioprotective and renoprotective effects in patients with heart failure and CKD, respectively.6), 8), 10), 20)
Other meta-analyses have studied the population of patients with CKD and T2DM, with conflicting results among them.12), 13), 21) A previous meta-analysis found no statistical effect of SGLT2i on stroke and cardiovascular mortality outcomes, diverging from our findings significantly.13) In addition, another meta-analysis found no significant benefit of SGLT2i therapy in stroke in patients with T2DM,22) which contrasts with our findings for the subgroup of patients with eGFR inferior to 45 mL/min/m2. One plausible explanation for our findings is the stratification according to CKD status and residual renal function, comprising a more homogeneous population in terms of baseline cardiovascular risk. As a result, the pooled population had a higher risk of incident MACE and stroke and, therefore, would benefit the most from SGLT2i therapy.
On the other hand, another meta-analysis found a significant benefit of SGLT2i therapy in terms of stroke for patients with lower eGFR. Our overall analysis further strengthens such findings by comprising a significantly larger population with the inclusion of the SCORED trial.9) As the authors previously stated, the underlying mechanisms for reducing stroke remain unclear. Even so, many mechanisms have been hypothesized. For instance, patients with T2DM have a higher incidence of risk factors for stroke, such as atrial fibrillation,23) and there is evidence of the benefit of SGLT2i therapy in terms of atrial fibrillation in this high-risk population.24)
Moreover, SGLT2i have been associated with reductions in endothelial dysfunction, inflammation, body weight, and blood pressure, which may play a role in the benefit of stroke rates in patients with lower eGFR and T2DM.25) Although there are scarce data supporting this finding, SGLT2i may exert more pronounced stroke prevention effects in patients with T2DM and more severe renal impairment, potentially through their additional renal protective mechanisms.26) Therefore, our results suggest a complex interplay between renal function, SGLT2i therapy, and stroke risk, highlighting the need for further investigation to elucidate the nuanced mechanisms involved.
Overall, several RCTs have been conducted since the publication of these previous meta-analyses, and the number of patients and outcomes investigated has significantly increased.5), 6), 7), 20) We also analyzed outcomes stratified according to renal function, showing consistent findings across different eGFR strata for the remaining outcomes.
Because SGLT2i inhibits glucose reabsorption in renal tubules, its action is expected to be eGFR-dependent.15), 19) SGLT2i also induces an acute, physiologic, and reversible reduction in eGFR, referred to as the eGFR dip. It was less clear, however, if this effect was of clinical significance until recent data—such as the EMPA-REG,8) VERTIS-CV,10) CREDENCE,5) and most recently, EMPA-KIDNEY7) studies—showed no association of SGLT2i use with progressive long-term kidney disease or worse cardiovascular outcomes. In fact, despite the initial transient reduction in eGFR, SGLT2i provides long-term renal benefits, such as attenuating CKD progression. Our meta-analysis demonstrates these effects and supports the efficacy of SGLT2i therapy even in the setting of lower baseline eGFR.
As recommended by the KDIGO 2022 guidelines on diabetes management in patients with CKD, SGLT2i therapy is a first-line therapy for reducing cardiorenal outcomes in this population, especially with regard to heart failure and the progression of CKD.27) Our findings support this recommendation and add other key cardiovascular outcomes, such as cardiovascular mortality, stroke, and MI, to support SGLT2i use in this patient population.
Our study has limitations. First, the definition of CKD varied slightly among studies, including definitions related to eGFR or urine albumin-creatinine ratio, as shown in Table 1. Second, the baseline cardiovascular risk may have also been heterogeneous in the patient population. DECLARE-TIMI 58,6) EMPA-REG,8) CANVAS,28) and VERTIS CV10) evaluated mainly patients with established cardiovascular disease or atherosclerotic cardiovascular disease, in contrast to CREDENCE5) and DAPA-CKD,29) which included patients with lower cardiovascular risks. Third, only a few studies reported data for the analyzed subgroups, which could lead to reduced statistical power in these analyses. Nevertheless, for the most part, the results remained statistically significant even in the subgroup analysis stratified by eGFR.
Finally, we performed a meta-regression for the outcome of MACE, which included only seven RCTs. The Cochrane Handbook recommends a minimum of ten studies for each examined covariate in meta-regression on the basis of the conventional rule of thumb of at least ten events per included covariate, which is used to reduce the likelihood of overfitting in logistic and Cox regression models. On the other hand, the handbook also emphasizes that it should not be taken as an inflexible rule. Based on a recent study that suggested that ordinary least squares linear regression may require considerably fewer observations per covariate than weighted random-effects meta-analysis, we decided to conduct meta-regressions using the results of seven large clinical trials.30) However, whether this also applies to our weighted meta-regression remains uncertain. As a result, these findings should only be viewed as a sensitivity analysis.
In this meta-analysis of 29,146 patients with T2DM and CKD, SGLT2i reduced all-cause and cardiovascular mortality, HHF, MACE, MI, and stroke across strata of eGFR. These findings support the use of SGLT2i as the mainstay therapy for these patients.
SUPPLEMENTARY MATERIALS
Definitions of composite outcomesSupplementary Table 1
SGLT2i significantly reduced cardiovascular mortality relative to placebo.Supplementary Figure 1
SGLT2i significantly reduced HHF relative to placebo in patients with eGFR <45 mL/min/1.73 m2 and eGFR 45–59 mL/min/1.73 m2.Supplementary Figure 2
SGLT2 inhibitors significantly reduced MACE relative to placebo in patients with eGFR <45 mL/min/1.73 m2 and eGFR 45–59 mL/min/1.73 m2.Supplementary Figure 3
The incidence of stroke was significantly different between subgroups according to eGFR (p=0.04; I2=77.3%).Supplementary Figure 4
MI was not significantly different between subgroups (p=0.67).Supplementary Figure 5
Quality assessment of the RCTs per Cochrane RoB-2.Supplementary Figure 6
Funnel plot for the outcome of MACE.Supplementary Figure 7
Bubble plot for meta-regressions for the outcome of MACE according to follow-up time and key baseline characteristics.Supplementary Figure 8
Funding:The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of Interest:The authors have no financial conflicts of interest.
Data Sharing Statement:The data generated in this study is available from the corresponding author upon reasonable request.
Author Contributions:
Conceptualization: Felix N.
Data curation: Felix N.
Formal analysis: Felix N, Nogueira A.
Investigation: Felix N, Gauza MM, Teixeira L, Guisso MES.
Methodology: Felix N, Nogueira A, Dagostin CS.
Project administration: Felix N.
Visualization: Felix N, Gauza MM, Teixeira L, Dagostin CS, Nogueira A.
Writing - original draft: Felix N, Gauza MM, Teixeira L, Guisso MES, Godoi A, Ribeiro SAG.
Writing - review & editing: Felix N, Gauza MM, Teixeira L, Guisso MES, Godoi A, Ribeiro SAG, Duque JC, Moura-Neto JA, Cardoso R.
References
-
The EMPA-KIDNEY Collaborative Group. Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117–127.
-
-
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022;102:S1–S127.
-
Figures
1 / 6
Tables
1 / 1
